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Abstract
Birth weight within the normal range is associated with a variety of adult-onset diseases, but the
mechanisms behind these associations are poorly understood1. Previous genome-wide association
studies identified a variant in the ADCY5 gene associated both with birth weight and type 2
diabetes, and a second variant, near CCNL1, with no obvious link to adult traits2. In an expanded
genome-wide association meta-analysis and follow-up study (up to 69,308 individuals of
European descent from 43 studies), we have now extended the number of genome-wide significant
loci to seven, accounting for a similar proportion of variance to maternal smoking. Five of the loci
are known to be associated with other phenotypes: ADCY5 and CDKAL1 with type 2 diabetes;
ADRB1 with adult blood pressure; and HMGA2 and LCORL with adult height. Our findings
highlight genetic links between fetal growth and postnatal growth and metabolism.
To understand further the genetic factors involved in fetal growth and its association with
adult diseases, we performed an expanded genome wide association study (GWAS) of birth
weight in up to 26,836 individuals of European ancestry from 18 studies (Stage 1;
Supplementary Table 1; Supplementary Figures 1 to 3; see Online Methods). After follow-
up analyses of 21 of the most strongly associated independent single nucleotide
polymorphisms (SNPs; P < 1×10−5) in additional European samples (Supplementary Tables
2 and 3), we identified novel associations with birth weight at four loci (P < 5×10−8), and
confirmed three previously reported associations2-4 (rs900400 near CCNL1, P = 3.6×10−38;
rs9883204 in ADCY5, P = 5.5×10−20; rs6931514 in CDKAL1; P = 1.5×10−18), in a joint
meta-analysis of up to 69,308 individuals (Table 1; Figure 1 and Supplementary Figure 4).
The index SNPs at the four newly-associated loci were rs1042725 in HMGA2 (P =
1.4×10−19), rs724577 in LCORL (P = 4.6×10−11), rs1801253 in ADRB1 (P = 3.6×10−9) and
rs4432842 at chromosome 5q11.2 (P = 4.6×10−8). The effect size estimates range from
0.034 SD to 0.072 SD per allele and equate approximately to changes in birth weight of 16
to 35g (Table 1). These estimates did not change materially in sensitivity analyses excluding
studies with self- or parentally-reported birth weight data and those without a measure of
gestational age (Supplementary Table 4).
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Through the cellular mechanisms of gametogenesis and fertilization, fetal genotype is
correlated with maternal genotype (r ≈ 0.5). Using up to 11,307 mother-child pairs from a
subset of studies, we found no evidence that the seven associations we observed at P <
5×10−8 are driven by the maternal, rather than the fetal, genotype (likelihood-ratio test P
>0.05; Table 1).
For five of the seven confirmed associations with birth weight, correspondence with GWAS
findings for adult traits (type 2 diabetes, blood pressure or height) provide clues to the
biological pathways involved. Two SNPs represent the same signals as known type 2
diabetes loci: ADCY5 (previously reported2) and CDKAL1 (previously examined in smaller
candidate gene studies of birth weight3-5). We observed similar z score effect size estimates
of the associations between each of these loci and ponderal index (calculated as weight/
length3 to indicate neonatal leanness), birth length and head circumference (Table 1),
suggesting a general effect on fetal growth. At both loci, the birth weight-lowering allele is
associated with greater type 2 diabetes risk2-4. This observation is consistent with the fetal
insulin hypothesis6, which proposes that common genetic variation influencing insulin
secretion or action, both in prenatal development and adult life, could partly explain
epidemiological correlations between lower birth weight and type 2 diabetes. The type 2
diabetes risk allele at ADCY5 is associated with a number of features suggesting impaired
insulin secretion: higher glucose levels after fasting and 2 hours after an oral glucose
challenge7,8; lower 2-hour insulin levels, adjusted for 2-hour glucose levels8; higher fasting
proinsulin (relative to mature insulin) levels9; and lower Homeostatic Model Assessment
(HOMA)-derived index of beta-cell function HOMA-B7 (Supplementary Table 5). The risk
allele at CDKAL1 is strongly associated with reduced insulin secretion in studies of
adults10. Given the key role of fetal insulin in prenatal growth, we hypothesize that the
ADCY5 and CDKAL1 risk alleles reduce fetal insulin levels, which mediate the associations
with birth weight.
To investigate whether type 2 diabetes susceptibility loci other than ADCY5 and CDKAL1
influence fetal growth, we tested the associations between 47 additional, published type 2
diabetes loci and birth weight in our Stage 1 meta-analysis. We observed more associations
with birth weight than expected by chance (Figure 2a), with 7 associations at P < 0.05, of
which 4 achieved P < 0.01 (MTNR1B-rs1387153, KCNQ1-rs231362, HHEX- IDE-
rs5015480 and GCK-rs4607517), including GCK at P=1×10−4. Meta-analysis of the HHEX-
IDE result with previously published data (total n = 51,583) strengthened the evidence of
association (P = 6.9×10−7; Supplementary Table 6). The type 2 diabetes risk alleles at
HHEX-IDE and KCNQ1 follow ADCY5 and CDKAL1 in being associated with lower birth
weight, providing additional support for the fetal insulin hypothesis, although the
associations can only explain a small fraction of the epidemiological association.
In contrast, the type 2 diabetes risk alleles at GCK and MTNR1B were associated with
higher birth weight (Figure 2b). Higher maternal glucose levels are associated with higher
offspring birth weight11, and both the GCK and MTNR1B loci influence fasting glucose
levels throughout the normal physiological range7. Consistent with this, and with previous
studies of the GCK variant12, the effect size estimates we observed for GCK and MTNR1B
were lower after adjustment for maternal genotype (Supplementary Figure 5). Well-powered
studies of mothers and offspring will be required to test formally the association between
maternal genotype and birth weight at these loci. The lack of a fetal association at GCK-
rs4607517 contrasts with the strong birth weight-lowering effects of rare, heterozygous fetal
GCK mutations13, and suggests that the common GCK variant does not influence insulin
secretion until postnatal life.
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The association with birth weight at ADRB1 rs1801253 (Arg389Gly) links prenatal growth
with blood pressure in adulthood since the same SNP is strongly associated with both
systolic and diastolic blood pressure (P<5×10−8)14. Epidemiological associations between
birth weight and systolic blood pressure (SBP) constitute some of the strongest evidence
supporting the fetal origins of adult disease15. Most studies report a linear inverse
association throughout the birth weight distribution, whereby lower birth weight is
associated with higher adult SBP. There is also evidence that birth weights at the high end of
the distribution are associated with higher SBP16. Based on the majority of studies, we
might therefore expect a fetal SBP-raising allele to be associated with lower birth weight.
However, the birth weight-lowering allele at rs1801253 (Gly389) is associated with lower
blood pressure in later life. We observed similar effect size estimates for associations
between ADRB1 and various birth measures (Table 1), suggesting a general effect on fetal
growth. We tested for associations between birth weight and 29 additional blood pressure
loci17 in our Stage 1 meta-analysis. While we did not observe strong evidence of deviation
from the null (Figure 2c), associations between the SBP-raising allele and lower birth weight
achieved P < 0.01 at GUCY1A3/GUCY1B3-rs13139571 (P=0.0008) and CYP17A1/
NT5C2-rs11191548 (P=0.009). These were little altered on adjustment for maternal
genotype (Figure 2d; Supplementary Table 7).
The associations with birth weight at the HMGA2 and LCORL loci link prenatal growth
with postnatal stature. At both loci, the birth weight-lowering allele is also associated with
lower adult height and associations are consistent with a primary effect on birth length
(Table 1). The HMGA2 SNP is also strongly associated with birth head circumference and is
known to associate with head circumference in infancy and intracranial volume in
adulthood18,19 suggesting a general effect on growth. Variation at LCORL has also been
associated with peak height velocity in infancy20, indicating an effect on growth in
childhood. When testing 178 additional published height loci21, we observed more
associations with birth weight than expected by chance (Figure 2e), indicating that many
adult height loci influence prenatal growth. Of all 180 loci, 132 show the same direction of
effect size estimate with birth weight as with height (binomial sign test P=3×10−10),
although there is no strong correlation between adult height and birth weight effect sizes
(Figure 2f). We did not observe any evidence that these associations were driven by
maternal genotypes (Supplementary Table 8).
The remaining two loci (near CCNL1 and on chromosome 5q11.2) are not known to be
associated with any other traits. The previously reported association near CCNL1 represents
the strongest association with birth weight, and shows a strong association with ponderal
index, but relatively weak associations with birth length and head circumference (Table 1),
strengthening the evidence that this locus primarily acts through non-skeletal growth. In a
subset of 7 studies with available postnatal data, the association had disappeared by 3
months of age (0.001 SD [95% CI: −0.030, 0.032] per rs900400 C-allele, relative to birth
weight: −0.084 SD [95%CI: −0.106, −0.062]; Supplementary Table 9; Supplementary
Figure 6), suggesting that the growth effects of the CCNL1 locus are specifically
intrauterine. Little is known about the birth weight locus at chromosome 5q11.2: the nearest
gene, ACTBL2, is approximately 400kb away and has no obvious link with fetal growth.
Associations at this locus are similar across the different anthropometric birth measures
(Table 1) and there are no associations with adult metabolic or anthropometric traits in
published studies (Supplementary Table 5).
We were interested to explore whether the same variants have any impact on birth weight in
other ethnic groups. Using data from a range of non-European studies, including those of
Middle Eastern, East and Southeast Asian and African origin (total n = 11,848;
Supplementary Table 10), we showed that the 7 SNPs together explained between 0.32%
Horikoshi et al. Page 6
Nat Genet. Author manuscript; available in PMC 2013 July 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
and 1.52% of the variance in birth weight, which was similar to that in Europeans (0.76%;
Supplementary Table 11; Supplementary Figures 7 and 8).
To conclude, we have identified four, and confirmed three loci associated with birth weight,
which explain a similar proportion of variance to maternal smoking exposure in pregnancy
(Supplementary Figure 9). The associations between five of the loci and adult traits (i)
highlight biological pathways of relevance to the fetal origins of type 2 diabetes, (ii) reveal
complexity in that type 2 diabetes risk alleles can be associated with either higher or lower
birth weight, (iii) illuminate a novel genetic link between fetal growth and adult blood
pressure and (iv) demonstrate substantial overlap between the genetics of prenatal growth
and adult height.
ONLINE METHODS
Stage 1: Genome-wide association (GWA) meta-analysis of birth weight: discovery
studies, genotyping and imputation
We combined 18 population-based European studies with birth weight and GWA data
available (total n = 26,836 individuals): two sub-samples from the 1958 British Birth Cohort
(B58C-WTCCC, n = 2,195; B58C-T1DGC, n = 2,037); the Avon Longitudinal Study of
Parents And Children (ALSPAC (Discovery); n = 1,418); the Children’s Hospital of
Philadelphia (CHOP , n = 7,380); the COpenhagen Prospective Study on Asthma in
Childhood (COPSAC-2000, n = 353); the European Prospective Investigation of Cancer
(EPIC, n = 1,478); the Erasmus Rucphen Family (ERF) study (n = 325); two sub-samples
from the Generation R study (Generation R (Discovery 1), n = 1,194; Generation R
(Discovery 2), n = 1,410); the Helsinki Birth Cohort Study (HBCS, n = 1,566); the Lifestyle
– Immune System – Allergy (LISA) study (n = 387); the Northern Finland 1966 Birth
Cohort (NFBC1966; n = 4,333); two sub-samples of singleton births from the Netherlands
Twin Register (NTR1, n = 414; NTR2, n = 247); the Orkney Complex Disease Study
(ORCADES, n = 328); the Prevention and Incidence of Asthma and Mite Allergy (PIAMA)
study (n = 368); the Raine study (RAINE, n = 1,105); and the Sorbs study (SORBS, n =
298).
While no systematic phenotypic difference is seen between the sub-samples of the 1958
British Birth Cohort, Generation R and Netherlands Twin Register, they were analyzed
separately because they were genotyped on different platforms and/or at different times.
Genotypes within each study were obtained using high-density SNP arrays and then imputed
for up to ~2.7 million HapMap SNPs (Phase II, release 21/22; http://
hapmap.ncbi.nlm.nih.gov/). The basic characteristics, exclusions applied (for example,
individuals of non-European ancestry, related individuals), genotyping, quality control and
imputation methods for each discovery sample are presented in Supplementary Table 1.
Statistical analysis within discovery studies
Birth weight (BW) was transformed to a z score ([BW value – mean BW]/s.d. BW) to
facilitate comparison of the data across studies. Multiple births and, where information was
available (see Supplementary Table 1), preterm births (gestational age <37 weeks) were
excluded from all analyses. The association between each SNP and birth weight was
assessed in each study sample using linear regression of birth weight z score against
genotype using an additive genetic model, with sex and, where available, gestational age as
covariables. Since gestational age was not available in all studies, we later performed a
sensitivity analysis, excluding the studies that did not have this covariable (see below). The
GWA analysis was performed using SNPTEST23, mach2qtl24, PLINK25 (http://
pngu.mgh.harvard.edu/purcell/plink/), GenABEL26 or ProbABEL27. Details of any
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additional corrections for study-specific population structure are given in Supplementary
Table 1. The data annotation, exchange and storage were facilitated by the SIMBioMS
platform (http://www.simbioms.org)28.
Meta-analysis of discovery studies
Prior to meta-analysis, SNPs with a minor allele frequency (MAF) < 0.01 and poorly
imputed SNPs (proper_info ≤ 0.4 (SNPTEST); r2hat ≤ 0.3 (mach2qtl)) were filtered.
Genomic control (GC)29 was applied to adjust the statistics generated within each cohort
(see Supplementary Table 1 for individual study λ values). Inverse variance fixed-effects
meta-analyses were undertaken using different software packages METAL (2009-10-10
release)30 and GWAMA (version 2.0.6)31 by two meta-analysts in parallel and compared to
obtain identical results. The meta-analysis results were obtained for a total of 2,684,393
SNPs. We applied a second GC correction to adjust the overall meta-analysis statistics (λ =
1.051) before selecting 21 SNPs for follow-up, which surpassed a P-value threshold of P <
1×10−5. This additional GC correction was, however, only applied for the purpose of
choosing the arbitrary significance threshold; we report here Stage 1 P-values after only the
first GC correction (see Supplementary Table 2) because a second GC correction is
generally considered to be over-conservative32. We additionally selected SNP rs6537307
(P=4.3×10−5), which is in linkage disequilibrium with a known HHIP height-associated
variant (HapMap r2 = 0.58 with rs685478333). Of the 22 selected SNPs, rs1004059 at
SYNP02L (P = 2.3×10−6) was available in only 8 studies since its MAF was close to 0.01.
After obtaining data from this SNP from all available Stage 1 studies, we observed a meta-
analysis P-value of P = 6×10−5, and so did not consider it further.
Stage 2: Follow-up of lead signals in European studies
Twenty-one SNPs selected from the discovery meta-analysis were taken forward for either
custom genotyping or analysis in studies with newly available genome-wide or
CardioMetabochip array genotyping (the latter included 6 of the 21 SNPs). If the index SNP
was unavailable, this was substituted with a closely correlated proxy from the HapMap (see
Supplementary Table 12). Of a total of 25 available studies (maximum combined n =
42,519), there were 14 studies with custom genotyping (n = 22,569 individuals), of which 2
studies later acquired additional in silico data (ALSPAC (Replication), n = 6,315 with
GWA; NFBC1986, n = 4,897 with CardioMetabochip). Eight further studies had in silico
GWA data (n = 13,992 individuals) and 3 further studies had in silico CardioMetabochip
array data (n = 5,958 individuals). Details of these studies are presented in Supplementary
Table 3. Since resources for custom genotyping were limited, the total number of analyzed
individuals varied by SNP, with 3 SNPs analysed in available in silico studies only (see
Supplementary Table 2). Within each study, we analysed the association between each
available SNP and birth weight z score in the same way as described above for Stage 1
studies.
Combined discovery and follow-up meta-analyses
We performed fixed effects inverse variance meta-analyses of the association between each
SNP and birth weight, including up to 43 discovery and follow-up samples of European
descent (maximum total n = 69,308). Individual study results for any SNP showing strong
evidence of deviation from Hardy-Weinberg Equilibrium (P <1×10−4) were excluded. Meta-
analyses were performed in parallel at two different study centres, using two software
packages in parallel (METAL 2009-10-10 release30 and GWAMA ver.2.0.631. We used
Cochran’s Q test and the derived inconsistency statistic, I2 34 to assess evidence of between-
study heterogeneity of effect size. Results that crossed the widely accepted genome-wide
significance threshold of P < 5×10−8 were considered to represent robust evidence of
association.
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Sensitivity analyses and phenotypic data quality checks
The ascertainment and availability of phenotype data varied widely among the 43 studies
(see Supplementary Tables 1 and 3). For example, birth weight was measured by trained
personnel in some studies, but in others was self-reported in adulthood. Gestational age was
not available as a covariable in all studies. We therefore performed further analyses to verify
data quality and check that the effect size estimates in our meta-analyses were not greatly
influenced by poor quality data or lack of adjustment for gestational age.
To identify any studies that showed unusual relationships between birth weight and other
phenotypes, we obtained from each study the percentage of variance in birth weight
explained by each of sex, parity, maternal smoking, gestational age and maternal pre-
pregnancy BMI as 100*adjusted-R2 value from linear regression of birth weight against
each individual trait. The observed relationships between birth weight and each related trait
were reasonably consistent across all of the 43 studies (see Supplementary Table 13 and
Supplementary Figure 9).
To assess whether adjustment for gestational age or measurement/recall bias of birth weight
influenced the associations between each of the 21 SNPs and birth weight, we repeated the
fixed-effects inverse-variance meta-analyses of the European results in three different sub-
sets of studies: (i) studies with birth weight collected by any method that adjusted for
gestational age (n = 35); (ii) studies with measured or medical record of birth weight that
adjusted for gestational age only where available (n = 26); (iii) studies with measured or
medical record of birth weight which also adjusted for gestational age (n = 24). We
compared the effect size estimates between each of these three meta-analyses and the overall
meta-analysis result (Supplementary Table 4).
Associations between birth weight and seven confirmed loci in non-European samples of
varying ancestry
Using 8 study samples of varying ancestry, we investigated the 7 loci, which showed
genome-wide significant associations with birth weight in the combined meta-analysis of
European discovery and follow-up studies. The 8 non-European studies were from East/
Southeast Asia (Chinese and Filipino), Africa (African-American, Mandinka and
Moroccan), Middle East (Arab, Turkish), and South America (Surinamese) (total n =
11,848; Supplementary Table 10). Samples were genotyped either by custom SNP assay (2
studies), CardioMetabochip (1 study) or genome-wide chip (5 studies). The index SNP from
the European meta-analysis was taken forward as the index SNP for the non-European
analyses, and associations with birth weight were analysed as described above. If the index
SNP was unavailable, it was substituted with a closely correlated ancestry-specific proxy
from the 1000 Genomes Pilot 1 YRI and JPT+CHB samples (released June 2010), which
was found using SNAP (http://www.broadinstitute.org/mpg/snap/; see Supplementary Table
12). In the 5 studies with GWA data, we considered all SNPs within 250-kb either side of
the European index SNP.
We performed three analyses:
i. Meta-analysis of single SNP associations with birth weight: we performed fixed-
effects inverse variance meta-analyses of available studies, as described above, for
each of the 7 loci.
ii. Ethnicity-specific regional analysis: we performed fixed effects inverse variance
meta-analyses for SNPs within the 500 kb surrounding the 7 index SNPs in an
ethnicity-specific manner for n = 2,135 East/Southeast Asian and n = 6,315
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African-American samples. We plotted the association results against chromosomal
position using LocusZoom (http://csg.sph.umich.edu/locuszoom/).
iii. Combined genotype risk score analysis: to assess the associations between birth
weight and the 7 confirmed loci in combination, we created a risk allele count
(RAC) by summing the birth-weight lowering alleles at each SNP. We performed
this analysis in 7 non-European studies in which 6 to 7 SNPs were available
(combined n = 11,014) and one representative European Stage 2 study (NFBC1986,
n = 4647). If a SNP was missing, all individuals were assigned a value of
2*frequency (HapMap, ethnicity-specific) of the birth weight-lowering allele. We
performed linear regression of birth weight z score against RAC (additive model),
with sex and gestational age (where available) as covariables. A genetic risk score,
weighted by effect size in Europeans, gave similar results in all non-European
studies (data not shown).
Variance explained
To estimate the percentage of variation in birth weight explained jointly by the 7 confirmed
birth weight loci, we obtained the adjusted-R2 from univariate linear regression of birth
weight against risk allele count in 6 non-European studies and one European study
(NFBC1986).
Analysis of additional anthropometric phenotypes measured at birth: birth length, birth
head circumference, ponderal index
Where available, in both Stage 1 and 2 European studies, we created within-study z scores
for birth length (available from 27 studies, n = 36,084), birth head circumference (20
studies, n = 23,277), and ponderal index (calculated as birth weight/length3, 27 studies, n =
35,836). The z scores were calculated by the same method as was used for birth weight. We
used linear regression to assess the association between each outcome and each of the 7
confirmed birth weight SNPs, with sex and gestational age (where available) as covariables.
We combined the results across studies using fixed-effects inverse variance meta-analysis.
Analysis of birth weight adjusted for birth length
Where both birth weight and birth length were available, we used linear regression to assess
the association between birth weight z score and the 7 confirmed birth weight SNPs, with
sex, gestational age (where available) and birth length as covariables. In the same set of
samples, we again performed linear regression to assess the association between birth weight
z score and SNP, with only sex and gestational age (where available) as covariables to allow
direct comparison of analyses with and without adjustment for birth length. Meta-analysis
was performed as above.
Analysis of birth weight adjusted for maternal genotype
To assess whether the birth weight associations at the seven confirmed birth weight loci
were independent of maternal genotype, we used mother-offspring pairs from up to 10
European studies with both maternal and fetal genotype available (Discovery n = 7,879,
Follow-up n = 3,428, total n = 11,307). Within each study, we performed linear regression
of birth weight z score against each of the SNPs, with sex, gestational age (where available)
and maternal genotype as covariables. For direct comparison, we repeated this without
maternal genotype, using only subjects for whom maternal genotype was available. Fixed
effects inverse variance meta-analysis was performed to combine results across studies for
(i) fetal genotype, and (ii) fetal genotype adjusted for maternal genotype. We performed a
likelihood ratio test to compare the model fit before and after adjustment for maternal
genotype.
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Analysis of associations between known type 2 diabetes, blood pressure, height and BMI
loci and birth weight
Of the seven confirmed birth weight loci, five had previously been associated with either
type 2 diabetes (CDKAL1 and ADCY5), blood pressure (ADRB1) or adult height (LCORL
and HMGA2). To assess whether association with birth weight is a common feature of loci
associated with these adult traits, we extracted results from our Stage 1 discovery meta-
analysis for 49 published type 2 diabetes SNPs7,22,35-48, 180 height SNPs21 and 30 blood
pressure SNPs14,17. To complement these analyses, we analyzed the associations between
the same sets of SNPs and birth weight z score in n = 5,327 mother-child pairs from the
ALSPAC study. We adjusted for sex and gestational age, recorded the results before and
after adjustment for maternal genotype and compared the fit of the two models using a
likelihood ratio test to assess evidence of confounding by maternal genotype. This was
particularly important for the analyses of type 2 diabetes SNPs since there is evidence that at
least two of the known loci influence birth weight via the maternal genotype49,50. For each
set of loci, we used the binomial probability (sign) test, available at http://faculty.vassar.edu/
lowry/binomialX.html, to assess whether there was more evidence of negative or positive
associations with birth weight than the 50% expected under the null.
For the HHEX-IDE (type 2 diabetes) locus, there are previously-published studies reporting
associations with birth weight, not all of which overlap with our Stage 1 Discovery
samples4,5. To obtain an approximate overall result for this locus, we therefore meta-
analyzed (inverse variance, fixed effects) our Stage 1 result with additional published data
from the ALSPAC, Inter99 and EFSOCH studies and in silico data available from Stage 2
(total n = 51,583). Two SNPs at the locus were represented in the meta-analysis: rs1111875
and rs5015480 (r2 = 0.97). Since the effect sizes for the published studies were in grams, we
first converted them to equivalent z-score values by dividing effect size estimates and 95%
confidence limits by 484 (the median standard deviation of birth weight in grams, from our
previous GWA study of birth weight)2.
Analysis of the associations between seven confirmed birth weight loci and adult
metabolic and anthopometric traits in publicly available results of GWA meta-analyses
We looked up the 7 confirmed birth weight index SNPs in publicly available published
meta-analysis datasets to assess their associations with adult metabolic and anthropometric
traits: (i) fasting glucose and fasting insulin7, (ii) fasting proinsulin9, (iii) triglycerides, total
cholesterol, low density lipoprotein (LDL) cholesterol and high density lipoprotein (HDL)
cholesterol51, (iv) height21 and (v) BMI52.
Analysis of the association between CCNL1 and weight up to 6 months in seven studies
We used available postnatal weight data from the EFSOCH, Generation R (Discovery 1),
Generation R (Discovery 2), LISA, HBCS, NFBC1966 and NFBC1986 (maximum total n =
15,090). Each study analysed weight data at the following time points, where available:
birth; 1 (+/− 0.2) month; 2 (+/− 0.2) months; 3 (+/− 0.3) months; 6 (+/− 0.4) months. Within
each study, we created weight-for-age z scores for each of the postnatal time points using
Growth Analyser 3.0 (http://www.growthanalyser.org; Dutch Growth Research Foundation,
Rotterdam, the Netherlands). The reference was a cohort of 475,588 children born between
1977 and 1981 in Sweden53. Birth weight was analysed as described above. At each
subsequent time point, we performed linear regression of weight-for-age z score against
rs900400 genotype (or designated proxy SNP, see Supplementary Table 12), with
gestational age at birth as a covariable. We combined the results across studies using fixed
effects inverse variance meta-analysis.
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Figure 1.
Regional plots of seven loci associated with birth weight at P<5×10−8. For each of the
CCNL1 (a), ADCY5 (b), HMGA2 (c), CDKAL1 (d), 5q11.2 (e), LCORL (f), and ADRB1
(g) regions, SNPs are plotted with their meta-analysis P values (as –log10 values) as a
function of genomic position (NCBI Build 36). In each panel, the European discovery stage
SNP taken forward for follow-up is represented by a purple circle (with global [discovery +
follow-up] meta-analysis P value), with its discovery P value denoted by a purple diamond.
Estimated recombination rates (taken from HapMap) are plotted to reflect the local LD
structure around the associated SNPs and their correlated proxies (according to a blue to red
scale from r2 = 0 to 1, based on pairwise r2 values from HapMap CEU). Gene annotations
were taken from the University of California Santa Cruz genome browser.
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Figure 2.
Associations between birth weight and known type 2 diabetes (T2D; a and b), systolic blood
pressure (SBP, c and d) or height (e and f) loci from the discovery meta-analysis of
N=26,836 individuals. Plots a, c and e are quantile-quantile plots: the black triangles
(associated with lower birth weight) and circles (associated with higher birth weight)
represent observed P-values after removing the loci that achieved P < 5×10−8 in the overall
meta-analysis, and the black line represents expected P-values under the null. The grey area
defines the approximate 95% confidence interval around the expected line. Plots b, d and f
show, respectively, the T2D, SBP or height effect size (left-hand y-axis), taken from
published meta-analyses14,17,21,22, against the birth weight effect size (x-axis), with a
superimposed frequency histogram showing the number of SNPs in each category of birth
weight effect size (right-hand y-axis). The odds ratios for type 2 diabetes are all obtained
from the published DIAGRAM+ Consortium meta-analysis22, the largest available reference
sample of European descent, and while they do not necessarily reach genome-wide
Horikoshi et al. Page 23
Nat Genet. Author manuscript; available in PMC 2013 July 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
significance in that sample, all loci have shown associations with type 2 diabetes at P <
5×10−8 (see Online Methods for details of published studies). Effect sizes are aligned to the
T2D risk allele or the SBP- or height-increasing allele. Colours indicate birth weight
association P-values: P<5e-08 (red); P>=5e-08 and P<0.001 (orange); P>=0.001 and P<0.01
(yellow); P>0.01 (white). The triangles in plot f are SNPs known to be associated with age
at menarche. There were more associations between height loci and higher birth weight than
expected under the null, and a slight excess of associations between T2D or SBP loci and
lower birth weight (binomial sign test P = 0.02, 0.09 and 3×10−10 for b, d and f,
respectively).
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